Our in vitro data support the hypothesis that the pharmacological modulation of LCAT, either with the recombinant protein or with small molecule activators, can improve the abnormal HDL phenotype in CKD, thus reducing serum pro-oxidative effects associated with low LCAT. Here, LCAT is linked to chronic kidney disease.